ClinicalTrials.gg
CompletedNCT02197572Updated Jan 23, 2023Results posted

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Sapanisertib in Advanced Solid Tumors, sponsored by Calithera Biosciences, Inc. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-23.

Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to characterize the effect of a single dose of 40 mg sapanisertib (MLN0128) on the electrocardiographic QT/QTc interval in participants with advanced solid tumors.

Read the detailed description

The drug being tested in this study is called sapanisertib (MLN0128). Sapanisertib is being tested to determine the effect of a single 40 mg dose on the electrocardiographic measure of the time between the start of the Q wave and the end of the T wave in the electrical cycle of the heart (QT)/rate corrected QT (QTc) interval in patients with advanced solid tumors. This study will look at electrocardiogram (ECG) results before and after a single dose of sapanisertib.

The study will enroll approximately 30 patients. All participants will receive a single 40 mg dose of sapanisertib capsules on Day 1. Participants may continue to receive sapanisertib for up to 1 year at a dose of up to 30 mg once weekly if a clinical benefit is being derived.

This multi-centre trial will be conducted in the United States. The overall time to participate in this study is up to 14 months. Participants will make 6 visits to the clinic and end of study visit 30 to 40 days after last dose of study drug for a follow-up assessment. Participants that continue treatment with sapanisertib will continue to make additional visits to the clinic once or twice every 4 weeks and the end of study visit 30 to 40 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Drug therapy
03

In context

Lead sponsor

Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women participants 18 years or older.
  • Must have a radiographically or clinically evaluable solid tumor (ECOG) performance status of 0 or 1.
  • Female participants who are for at least 1 year before the screening visit, OR are surgically sterile, OR if they are of , agree to practice 2 effective methods of , at the same time, from the time of signing the through 3 months after the last dose of study drug, OR agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception.)
  • Male participants, even if surgically sterilized (i.e., status post vasectomy), who agree to practice effective barrier contraception during the entire study treatment period and through 3 months after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)
  • Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  • Ability to swallow oral medications, willingness to perform mucositis prophylaxis, and suitable venous access for the study-required blood sampling.

Exclusion criteria

Exclusion Criteria

  • Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period.
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  • Treatment with any products within 14 days before the first dose of study drug and systemic anticancer therapy within 28 days before the first dose of study drug.
  • Untreated or history of or spinal cord compression.
  • Tumors with involvement of the mediastinum.
  • Failure to recover from the reversible effects of prior anticancer therapies with the exception of alopecia, and after-effects associated with prior tyrosine kinase inhibitor therapy such as hair depigmentation, hypothyroidism, and/or splinter hemorrhage.
  • Systemic (inhalers are allowed) within 7 days before the first dose of study drug.
  • Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown or other reason that may alter the absorption of Sapanisertib.
  • Diagnosis of diabetes mellitus; participants with a history of transient glucose intolerance due to corticosteroid administration may be enrolled if all other inclusion/exclusion criteria are met.
  • Significant active cardiovascular or pulmonary disease at study entry
  • History of arrhythmia requiring an implantable cardiac defibrillator
  • comorbidities such as uncontrolled pulmonary disease, active central nervous system disease, active infection, serious infection within 14 days before the first dose of study drug, or any other condition that could compromise study participation by the participant.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Sapanisertib

    Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).

    Drug: Sapanisertib

Interventions

  • Sapanisertib capsules.

    Also known as: MLN0128, INK128, TAK-228

06

What researchers measure

Primary outcomes

  1. Mean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval

    The mean changes of QTcI from time-matched baseline was measured by electrocardiogram (ECG) to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcI interval.

    Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose

Secondary outcomes

  1. Number of Participants With Atleast One Adverse Event (AE) and Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)

  2. Number of Participants With Potentially Clinically Significant Abnormal Laboratory Values Reported as AE

    The laboratory parameters included clinical chemistry, hematology, and urinalysis. Any abnormal change in the laboratory values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)

  3. Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Reported as AE

    Vital sign measurements included blood pressure (diastolic and systolic), heart rate, and temperature. Any abnormal change in the vital sign values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)

  4. Mean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval With Bazett Correction (QTcB)

    The mean changes of QTcB from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcB interval.

    Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose

  5. Mean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval Fridericia Correction (QTcF)

    The mean changes of QTcF from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcF interval.

    Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose

  6. Change From Time-Matched Baseline in QRS Interval

    QRS interval is defined as the time between the start of the Q wave and end of the S wave on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QRS interval.

    Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose

  7. Change From Time-Matched Baseline in PR Interval

    PR interval is defined as the time between the start of the P wave and the beginning of the QRS complex on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of PR interval.

    Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose

  8. Change From Time-Matched Baseline in Heart Rate

    Heart rate was assessed using the ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measure mixed effects linear model. A negative change from baseline indicates decrease in heart rate.

    Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose

  9. Cmax: Maximum Observed Plasma Concentration for Sapanisertib

    Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose

  10. Tmax: Time to Reach Cmax for Sapanisertib

    Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose

  11. AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration for Sapanisertib

    Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose

  12. AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib

    Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose

  13. T1/2: Terminal Elimination Half-life for Sapanisertib

    Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose

07

Results

Posted Mar 3, 2020

Participant flow

Participants took part in the study at 5 investigative sites in the United States from 15 Sep 2014 to 28 Feb 2019.

Participant flow — Overall Study
MilestoneSapanisertib
Started44
Completed0
Not completed44
Withdrew: Progressive disease28
Withdrew: Withdrawal by subject9
Withdrew: Adverse event3
Withdrew: Reason not specified4

Outcome measures

PrimaryMean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval

The mean changes of QTcI from time-matched baseline was measured by electrocardiogram (ECG) to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcI interval.

Time frame:
Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Reported as:
Mean · msec
Mean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval
msecSapanisertib
Change from Baseline at 0.25 Hours Postdose-1.3 ± 9.5
Change from Baseline at 0.5 Hours Postdose-7.7 ± 9.8
Change from Baseline at 1 Hour Postdose-1.1 ± 11.5
Change from Baseline at 1.5 Hours Postdose-2.0 ± 12.5
Change from Baseline at 2 Hours Postdose-4.2 ± 11.2
Change from Baseline at 2.5 Hours Postdose-6.9 ± 10.6
Change from Baseline at 3 Hours Postdose-8.5 ± 11.2
Change from Baseline at 4 Hours Postdose-6.6 ± 9.3
Change from Baseline at 6 Hours Postdose-8.8 ± 15.6
Change from Baseline at 8 Hours Postdose-1.3 ± 14.1
Change from Baseline at 10 Hours Postdose-5.6 ± 17.5
Change from Baseline at 24 Hours Postdose7.1 ± 25.4
Change from Baseline at 48 Hours Postdose3.1 ± 17.8
Statistical analysis
  • Sapanisertib · Least squares mean: -2.2
  • Sapanisertib · Least squares mean: -8.3
  • Sapanisertib · Least squares mean: -1.8
  • Sapanisertib · Least squares mean: -2.7
  • Sapanisertib · Least squares mean: -5.0
  • Sapanisertib · Least squares mean: -7.6
  • Sapanisertib · Least squares mean: -9.1
  • Sapanisertib · Least squares mean: -7.2
  • Sapanisertib · Least squares mean: -8.8
  • Sapanisertib · Least squares mean: -2.2
  • Sapanisertib · Least squares mean: -6.6
  • Sapanisertib · Least squares mean: 7.1
  • Sapanisertib · Least squares mean: 2.8
SecondaryNumber of Participants With Atleast One Adverse Event (AE) and Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Atleast One Adverse Event (AE) and Serious Adverse Event (SAE)
ParticipantsSapanisertib
AE43
SAE18
SecondaryNumber of Participants With Potentially Clinically Significant Abnormal Laboratory Values Reported as AE

The laboratory parameters included clinical chemistry, hematology, and urinalysis. Any abnormal change in the laboratory values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormal Laboratory Values Reported as AE
ParticipantsSapanisertib
Blood Creatinine Increased2
Blood Triglycerides Increased2
Hyperglycemia8
Hypertriglyceridemia1
Hypomagnesemia1
Hypophosphatemia2
Vitamin D Deficiency2
Anemia3
Thrombocytopenia1
SecondaryNumber of Participants With Potentially Clinically Significant Abnormal Vital Signs Reported as AE

Vital sign measurements included blood pressure (diastolic and systolic), heart rate, and temperature. Any abnormal change in the vital sign values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Reported as AE
ParticipantsSapanisertib
Hypotension1
Postoperative Fever1
Pyrexia4
SecondaryMean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval With Bazett Correction (QTcB)

The mean changes of QTcB from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcB interval.

Time frame:
Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Reported as:
Mean · msec
Mean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval With Bazett Correction (QTcB)
msecSapanisertib
Change from Baseline at 0.25 Hours Postdose-1.9 ± 9.7
Change from Baseline at 0.5 Hours Postdose-9.8 ± 12.1
Change from Baseline at 1 Hour Postdose-2.0 ± 12.4
Change from Baseline at 1.5 Hours Postdose-3.1 ± 13.5
Change from Baseline at 2 Hours Postdose-5.1 ± 11.4
Change from Baseline at 2.5 Hours Postdose-7.5 ± 10.6
Change from Baseline at 3 Hours Postdose-8.3 ± 14.6
Change from Baseline at 4 Hours Postdose-8.5 ± 8.7
Change from Baseline at 6 Hours Postdose-5.9 ± 12.2
Change from Baseline at 8 Hours Postdosen1.9 ± 13.7
Change from Baseline at 10 Hours Postdose-4.4 ± 15.3
Change from Baseline at 24 Hours Postdose11.9 ± 17.0
Change from Baseline at 48 Hours Postdose7.6 ± 14.9
SecondaryMean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval Fridericia Correction (QTcF)

The mean changes of QTcF from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcF interval.

Time frame:
Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Reported as:
Mean · msec
Mean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval Fridericia Correction (QTcF)
msecSapanisertib
Change from Baseline at 0.25 Hours Postdose-1.3 ± 8.5
Change from Baseline at 0.5 Hours Postdose-5.0 ± 10.6
Change from Baseline at 1 Hour Postdose2.1 ± 12.0
Change from Baseline at 1.5 Hours Postdose0.6 ± 12.7
Change from Baseline at 2 Hours Postdose-3.3 ± 12.2
Change from Baseline at 2.5 Hours Postdose-7.0 ± 11.1
Change from Baseline at 3 Hours Postdose-7.4 ± 13.2
Change from Baseline at 4 Hours Postdose-7.7 ± 10.3
Change from Baseline at 6 Hours Postdose-10.1 ± 13.0
Change from Baseline at 8 Hours Postdose-4.0 ± 15.1
Change from Baseline at 10 Hours Postdose-11.9 ± 16.1
Change from Baseline at 24 Hours Postdose0.8 ± 16.0
Change from Baseline at 48 Hours Postdose2.5 ± 13.2
SecondaryChange From Time-Matched Baseline in QRS Interval

QRS interval is defined as the time between the start of the Q wave and end of the S wave on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QRS interval.

Time frame:
Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Reported as:
Mean · msec
Change From Time-Matched Baseline in QRS Interval
msecSapanisertib
Change from Baseline at 0.25 Hours Postdose-0.7 ± 3.3
Change from Baseline at 0.5 Hours Postdose-1.4 ± 3.3
Change from Baseline at 1 Hour Postdose-2.8 ± 2.9
Change from Baseline at 1.5 Hours Postdose-1.8 ± 4.1
Change from Baseline at 2 Hours Postdose-1.4 ± 4.0
Change from Baseline at 2.5 Hours Postdose-2.3 ± 4.7
Change from Baseline at 3 Hours Postdose-2.4 ± 3.2
Change from Baseline at 4 Hours Postdose-2.9 ± 3.2
Change from Baseline at 6 Hours Postdose-1.3 ± 3.0
Change from Baseline at 8 Hours Postdosen-0.8 ± 4.1
Change from Baseline at 10 Hours Postdose-4.0 ± 6.5
Change from Baseline at 24 Hours Postdose-1.4 ± 4.0
Change from Baseline at 48 Hours Postdose0.2 ± 5.3
SecondaryChange From Time-Matched Baseline in PR Interval

PR interval is defined as the time between the start of the P wave and the beginning of the QRS complex on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of PR interval.

Time frame:
Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Reported as:
Mean · msec
Change From Time-Matched Baseline in PR Interval
msecSapanisertib
Change from Baseline at 0.25 Hours Postdose-1.8 ± 13.9
Change from Baseline at 0.5 Hours Postdose-0.8 ± 13.6
Change from Baseline at 1 Hour Postdose0.7 ± 11.5
Change from Baseline at 1.5 Hours Postdose-0.7 ± 11.4
Change from Baseline at 2 Hours Postdose-1.7 ± 9.3
Change from Baseline at 2.5 Hours Postdose0.1 ± 11.7
Change from Baseline at 3 Hours Postdose-2.7 ± 10.8
Change from Baseline at 4 Hours Postdose-1.9 ± 13.3
Change from Baseline at 6 Hours Postdose-8.9 ± 13.2
Change from Baseline at 8 Hours Postdosen-7.3 ± 11.4
Change from Baseline at 10 Hours Postdose-12.3 ± 11.5
Change from Baseline at 24 Hours Postdose-6.8 ± 15.7
Change from Baseline at 48 Hours Postdose-2.9 ± 20.7
SecondaryChange From Time-Matched Baseline in Heart Rate

Heart rate was assessed using the ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measure mixed effects linear model. A negative change from baseline indicates decrease in heart rate.

Time frame:
Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Reported as:
Mean · beats per minute (bpm)
Change From Time-Matched Baseline in Heart Rate
beats per minute (bpm)Sapanisertib
Change from Baseline at 0.25 Hours Postdose-0.9 ± 5.7
Change from Baseline at 0.5 Hours Postdose-4.7 ± 5.9
Change from Baseline at 1 Hour Postdose-4.2 ± 6.6
Change from Baseline at 1.5 Hours Postdose-3.7 ± 6.0
Change from Baseline at 2 Hours Postdose-1.0 ± 8.2
Change from Baseline at 2.5 Hours Postdose-0.3 ± 4.8
Change from Baseline at 3 Hours Postdose-0.3 ± 7.2
Change from Baseline at 4 Hours Postdose-0.4 ± 10.1
Change from Baseline at 6 Hours Postdose4.8 ± 6.3
Change from Baseline at 8 Hours Postdose7.0 ± 9.7
Change from Baseline at 10 Hours Postdose7.9 ± 9.2
Change from Baseline at 24 Hours Postdose12.4 ± 11.8
Change from Baseline at 48 Hours Postdose5.0 ± 9.8
SecondaryCmax: Maximum Observed Plasma Concentration for Sapanisertib
Time frame:
Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Sapanisertib
ng/mLSapanisertib
Cmax: Maximum Observed Plasma Concentration for Sapanisertib337.1 ± 178.27
SecondaryTmax: Time to Reach Cmax for Sapanisertib
Time frame:
Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Median · hours
Tmax: Time to Reach Cmax for Sapanisertib
hoursSapanisertib
Tmax: Time to Reach Cmax for Sapanisertib1.5167 (0.500 to 24.000)
SecondaryAUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration for Sapanisertib
Time frame:
Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Mean · h*ng/mL
AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration for Sapanisertib
h*ng/mLSapanisertib
AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration for Sapanisertib2875.7406 ± 2110.90918
SecondaryAUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib
Time frame:
Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Mean · h*ng/mL
AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib
h*ng/mLSapanisertib
AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib2992.5394 ± 2405.41705
SecondaryT1/2: Terminal Elimination Half-life for Sapanisertib
Time frame:
Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Median · hours
T1/2: Terminal Elimination Half-life for Sapanisertib
hoursSapanisertib
T1/2: Terminal Elimination Half-life for Sapanisertib9.0682 (4.477 to 16.867)

Adverse events

Collected over From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sapanisertib2/44 (4.5%)18/44 (40.9%)43/44 (97.7%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSapanisertib
Flank PainMusculoskeletal and connective tissue disorders2/44
Small Intestinal ObstructionGastrointestinal disorders1/44
Small Intestinal PerforationGastrointestinal disorders1/44
StomatitisGastrointestinal disorders1/44
FatigueGeneral disorders1/44
Non-Cardiac Chest PainGeneral disorders1/44
Bile Duct ObstructionHepatobiliary disorders1/44
HypersensitivityImmune system disorders1/44
AppendicitisInfections and infestations1/44
PyelonephritisInfections and infestations1/44
Most frequent other events
Showing 10 of 41
Most frequent other events
EventSapanisertib
NauseaGastrointestinal disorders35/44
FatigueGeneral disorders28/44
VomitingGastrointestinal disorders25/44
Decreased AppetiteMetabolism and nutrition disorders22/44
DiarrhoeaGastrointestinal disorders15/44
Weight DecreasedInvestigations14/44
Urinary Tract InfectionInfections and infestations13/44
StomatitisGastrointestinal disorders10/44
ConstipationGastrointestinal disorders9/44
Back PainMusculoskeletal and connective tissue disorders9/44

Baseline characteristics

Safety population included all participants who received at least 1 dose of Sapanisertib.

Age, Continuous
Age, Continuous(years)Sapanisertib
Mean58.6 ± 12.24
Sex: Female, Male
Sex: Female, Male(Participants)Sapanisertib
Female28
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sapanisertib
Hispanic or Latino7
Not Hispanic or Latino29
Unknown or Not Reported8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sapanisertib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American9
White30
More than one race0
Unknown or Not Reported5
Height
Height(cm)Sapanisertib
Mean166.8 ± 8.61
Weight
Weight(kg)Sapanisertib
Mean74.9 ± 16.08
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Sapanisertib
Mean27.141 ± 5.8591
08

Study locations

5 sites
  • Sarasota, Florida, United States
  • Saint Louis, Missouri, United States
  • Bronx, New York, United States
  • Oklahoma City, Oklahoma, United States
  • Dallas, Texas, United States
09

References and documents

Publications

  • Patel C, Goel S, Patel MR, Rangachari L, Wilbur JD, Shou Y, Venkatakrishnan K, Lockhart AC. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2020 Oct;9(7):876-888. doi: 10.1002/cpdd.808. Epub 2020 Jun 2. PubMed 32488989 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Jun 2016, 20 months.

Results were first posted in Mar 2020, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2014
First posted
Jul 22, 2014
StartActual
Sep 15, 2014
Primary completionActual
Jun 10, 2016
CompletionActual
Feb 28, 2019
Results first posted
Mar 3, 2020
Last update
Jan 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02197572
Responsible party
Sponsor
First posted
Jul 22, 2014
Start date
Sep 15, 2014
Primary completion
Jun 10, 2016
Completion
Feb 28, 2019
Results posted
Mar 3, 2020
Last update
Jan 23, 2023

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sapanisertib

Start the discussion